Summary of transactions
Patrick Plewman, who serves as senior vice president for Diagnostic Services at Quest Diagnostics (NYSE: DGX), reported a series of equity transactions in a Form 4 filing with the Securities and Exchange Commission.
On February 19, Plewman sold 958 shares of Quest Diagnostics common stock at $204.83 per share, a transaction that amounted to approximately $196,227.
Additional sales to cover tax withholding
The filing also documents two disposals on February 18 intended to satisfy tax withholding obligations: 244 shares sold at $210.01 and 293 shares sold at $206.99. Those two sales together total $111,890.
Equity awards and option grants
On the same day as the Feb. 18 filings, Plewman acquired 1,952 shares of Quest Diagnostics stock that stemmed from a restricted stock unit award and were recorded with a value of $0. The filing also shows a grant of 9,009 non-qualified stock options. The options become exercisable beginning on the first anniversary of the grant date, February 18, 2026.
Holdings after the transactions
Following the reported sales, award and option grant, Plewman directly owns 15,838 shares of Quest Diagnostics common stock, according to the Form 4 filing.
Market context and valuation note
Quest Diagnostics shares have been trading near their 52-week high of $213.20, with the stock up 17% year-to-date. An InvestingPro analysis cited in the filing indicates the stock presently appears overvalued relative to its Fair Value while noting the company’s solid fundamentals and a market capitalization of $22.3 billion.
Recent operating performance
Quest Diagnostics reported fourth-quarter 2025 results that surpassed analyst expectations. The company posted earnings per share of $2.42 versus a forecast of $2.36 and reported revenue of $2.81 billion compared with an anticipated $2.75 billion. The earnings release prompted a positive reaction in pre-market trading, and the filing notes that analysts’ prior projections were consistent with the company’s reported outturn.
Record and regulatory note
All of the insider equity transactions were disclosed via the SEC Form 4, as required for reporting officer and director trades. The filings show both open-market sales to satisfy tax liabilities and the simultaneous recording of compensation awards structured as restricted stock units and options.
This report presents the transaction details and the company’s reported quarterly results. It confines itself to the information disclosed in the company’s filings and published quarterly figures without offering further interpretation or investment guidance.